{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:09:31Z","timestamp":1791659371859,"version":"4.3.4"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The treatment of metastatic breast cancer (mBC) has evolved significantly in the past several years with the approval of new targeted agents. Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate with a topoisomerase I inhibitor payload, is a new addition to the class of therapies that target the human epidermal growth factor 2 (HER2) receptor. T-DXd was approved in the US in December 2019 for patients with HER2-positive metastatic or unresectable breast cancer who have received 2 or more prior anti-HER2\u2013based regimens in the metastatic setting. In the DESTINY-Breast01 phase II trial (NCT03248492), T-DXd demonstrated high rates of durable responses in heavily pretreated patients with HER2-positive mBC, with a confirmed objective response rate of 62%, median duration of response of 18.2 months, and median progression-free survival of 19.4 months. In addition to efficacy, successful implementation of any new anticancer therapy includes learning how to prevent, monitor, and manage treatment-related adverse events. As T-DXd becomes more widely used, information can be gained from real-world clinical practices, institutional approaches, and the collaboration of multidisciplinary oncology teams who treat patients with T-DXd. This article reviews practical insights and management of nausea and vomiting, neutropenia, interstitial lung disease, risk of cardiotoxicity, and other adverse events associated with T-DXd administration from the perspective of health care providers who have experience utilizing T-DXd.<\/jats:p>","DOI":"10.1093\/oncolo\/oyac107","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T12:16:15Z","timestamp":1654085775000},"page":"637-645","source":"Crossref","is-referenced-by-count":35,"title":["Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4885-1157","authenticated-orcid":false,"given":"Aditya","family":"Bardia","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Harvard University , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Harnden","sequence":"additional","affiliation":[{"name":"Breast Oncology Program, Inova Schar Cancer Institute , Fairfax, VA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Mauro","sequence":"additional","affiliation":[{"name":"Breast Oncology Program, Inova Schar Cancer Institute , Fairfax, VA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Pennisi","sequence":"additional","affiliation":[{"name":"Breast Oncology Program, Inova Schar Cancer Institute , Fairfax, VA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Armitage","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, H. Lee Moffitt Cancer Center & Research Institute , Tampa, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem","family":"Soliman","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, H. Lee Moffitt Cancer Center & Research Institute , Tampa, FL , USA"},{"name":"Experimental Therapeutics Program, H. Lee Moffitt Cancer Center & Research Institute , Tampa, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"key":"2022080910393724700_CIT0001","author":"American Cancer Society."},{"issue":"5","key":"2022080910393724700_CIT0002","doi-asserted-by":"crossref","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2022080910393724700_CIT0003","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"138","author":"Wolff","year":"2014","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"2022080910393724700_CIT0004","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/bjc.1991.103","article-title":"The long term prognostic significance of c-erbB-2 in primary breast cancer","volume":"63","author":"Winstanley","year":"1991","journal-title":"Br J Cancer"},{"issue":"1","key":"2022080910393724700_CIT0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2014.0008","article-title":"Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy","volume":"12","author":"Seah","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"2022080910393724700_CIT0006","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"2022080910393724700_CIT0007","year":"2021"},{"issue":"7","key":"2022080910393724700_CIT0008","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci"},{"issue":"7","key":"2022080910393724700_CIT0009","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"2022080910393724700_CIT0010"},{"key":"2022080910393724700_CIT0011","article-title":"Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer: updated survival results from a phase 2 trial (DESTINY-Breast01).","author":"Saura","year":"2021"},{"key":"2022080910393724700_CIT0012","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"key":"2022080910393724700_CIT0013","year":"2021"},{"key":"2022080910393724700_CIT0014","year":"2020"},{"key":"2022080910393724700_CIT0015","year":"2019"},{"key":"2022080910393724700_CIT0016","year":"2020"},{"key":"2022080910393724700_CIT0017","article-title":"Updated results from DESTINY-Breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer.","author":"Modi","year":"2020"},{"key":"2022080910393724700_CIT0018","year":"2021"},{"issue":"4","key":"2022080910393724700_CIT0019","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000511049","article-title":"Management of chemotherapy-induced nausea and vomiting with trastuzumab deruxtecan: a case series","volume":"16","author":"Stankowicz","year":"2021","journal-title":"Breast Care"},{"key":"2022080910393724700_CIT0020","year":"1991"},{"key":"2022080910393724700_CIT0021","year":"2002"},{"key":"2022080910393724700_CIT0022","year":"2022"},{"issue":"4","key":"2022080910393724700_CIT0023","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.resinv.2013.09.001","article-title":"Consensus statement for the diagnosis and treatment of drug-induced lung injuries","volume":"51","author":"Kubo","year":"2013","journal-title":"Respir Investig"},{"issue":"9","key":"2022080910393724700_CIT0024","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1164\/rccm.201907-1324ED","article-title":"The 2018 diagnosis of idiopathic pulmonary fibrosis guidelines: surgical lung biopsy for radiological pattern of probable usual interstitial pneumonia is not mandatory","volume":"200","author":"Raghu","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2022080910393724700_CIT0025","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10741-018-9731-y","article-title":"Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology","volume":"24","author":"Kostakou","year":"2019","journal-title":"Heart Fail Rev"},{"issue":"8","key":"2022080910393724700_CIT0026","doi-asserted-by":"crossref","first-page":"904","DOI":"10.6004\/jnccn.2010.0067","article-title":"NCCN clinical practice guidelines: cancer-related fatigue","volume":"8","author":"Berger","year":"2010","journal-title":"J Natl Compr Canc Netw"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/8\/637\/45293643\/oyac107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/8\/637\/45293643\/oyac107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T10:41:08Z","timestamp":1660041668000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/8\/637\/6596617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,6,1]]},"published-print":{"date-parts":[[2022,8,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac107","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,6,1]]}}}